First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.
Chung HJ, Kondoh C, Bae WK, Tamada S, Matsubara N, Lee HJ, Mizuno R, Anai S, Kimura G, Tomita Y, Chang CH, Chang JW, Lin J, Perini RF, Molife LR, Powles T, Rini BI, Uemura H.
Chung HJ, et al. Among authors: lee hj.
Jpn J Clin Oncol. 2025 Jan 16:hyae182. doi: 10.1093/jjco/hyae182. Online ahead of print.
Jpn J Clin Oncol. 2025.
PMID: 39815637